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Abstract
Hyperparathyroidism is deﬁned as excessive parathyroid hormone production. The diagnosis is made through biochemical testing, in
which imaging has no role. However, imaging is appropriate for preoperative parathyroid gland localization with the intent of surgical
cure. Imaging is particularly useful in the setting of primary hyperparathyroidism whereby accurate localization of a single parathyroid
adenoma can facilitate minimally invasive parathyroidectomy. Imaging can also be useful to localize ectopic or supernumerary
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Disclaimer: The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of
speciﬁed medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment.
Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for
evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this
document. The availability of equipment or personnel may inﬂuence the selection of appropriate imaging procedures or treatments. Imaging techniques classiﬁed as investigational by the FDA
have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any
speciﬁc radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

Copyright ª 2021 American College of Radiology

S406

1546-1440/21/$36.00 n https://doi.org/10.1016/j.jacr.2021.08.013

parathyroid glands and detail anatomy, which may impact surgery. This document summarizes the literature and provides imaging
recommendations for hyperparathyroidism including primary hyperparathyroidism, recurrent or persistent primary hyperparathyroidism
after parathyroid surgery, secondary hyperparathyroidism, and tertiary hyperparathyroidism. Recommendations include ultrasound, CT
neck without and with contrast, and nuclear medicine parathyroid scans.
The American College of Radiology Appropriateness Criteria are evidence-based guidelines for speciﬁc clinical conditions that are
reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current
medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness
Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of
imaging and treatment procedures for speciﬁc clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion
may supplement the available evidence to recommend imaging or treatment.
Key Words: Appropriateness Criteria, Appropriate Use Criteria, AUC, Hyperparathyroidism, Parathyroid adenoma, Primary hyperparathyroidism, Recurrent hyperparathyroidism, Secondary hyperparathyroidism, Tertiary hyperparathyroidism
J Am Coll Radiol 2021;18:S406-S422. Copyright ª 2021 American College of Radiology

ACR Appropriateness Criteria Parathyroid Adenoma. Variants 1 to 4 and Tables 1 and 2.

Variant 1. Adult or child. Primary hyperparathyroidism. Initial imaging.
Procedure

Appropriateness Category

Relative Radiation Level

US parathyroid

Usually Appropriate

O

Sestamibi scan and pertechnetate thyroid scan

Usually Appropriate

☢☢☢

CT neck without and with IV contrast

Usually Appropriate

☢☢☢

Sestamibi dual-phase scan neck

Usually Appropriate

☢☢☢

Sestamibi dual-phase scan with SPECT or
SPECT/CT neck
Sestamibi scan and I-123 thyroid scan

Usually Appropriate

☢☢☢

Usually Appropriate

☢☢☢

Sestamibi scan and I-123 thyroid scan with
SPECT or SPECT/CT neck
Sestamibi scan and pertechnetate thyroid scan
with SPECT or SPECT/CT neck
MRI neck with IV contrast

Usually Appropriate

☢☢☢

Usually Appropriate

☢☢☢

May Be Appropriate

O

MRI neck without and with IV contrast

May Be Appropriate

O

CT neck with IV contrast

May Be Appropriate

☢☢☢

Venous sampling parathyroid

Usually Not Appropriate

Varies

MRI neck without IV contrast

Usually Not Appropriate

O

Usually Not Appropriate

☢☢☢

CT neck without IV contrast
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Variant 2. Adult or child. Primary hyperparathyroidism, recurrent or persistent after parathyroid surgery. Initial imaging.
Procedure

Appropriateness Category

Relative Radiation Level

US parathyroid

Usually Appropriate

O

Sestamibi scan and pertechnetate thyroid scan

Usually Appropriate

☢☢☢

CT neck without and with IV contrast

Usually Appropriate

☢☢☢

Sestamibi dual-phase scan neck

Usually Appropriate

☢☢☢

Sestamibi dual-phase scan with SPECT or
SPECT/CT neck
Sestamibi scan and I-123 thyroid scan

Usually Appropriate

☢☢☢

Usually Appropriate

☢☢☢

Sestamibi scan and I-123 thyroid scan with
SPECT or SPECT/CT neck
Sestamibi scan and pertechnetate thyroid scan
with SPECT or SPECT/CT neck
Venous sampling parathyroid

Usually Appropriate

☢☢☢

Usually Appropriate

☢☢☢

May Be Appropriate

Varies

MRI neck with IV contrast

May Be Appropriate

O

MRI neck without and with IV contrast

May Be Appropriate

O

CT neck with IV contrast

May Be Appropriate

☢☢☢

MRI neck without IV contrast

Usually Not Appropriate

O

CT neck without IV contrast

Usually Not Appropriate

☢☢☢

Variant 3. Adult or child. Secondary hyperparathyroidism. Initial imaging.
Procedure

Appropriateness Category

Relative Radiation Level

US parathyroid

Usually Appropriate

O

CT neck without and with IV contrast

Usually Appropriate

☢☢☢

Sestamibi dual-phase scan neck

Usually Appropriate

☢☢☢

Sestamibi dual-phase scan with SPECT or
SPECT/CT neck
Sestamibi scan and I-123 thyroid scan with
SPECT or SPECT/CT neck
Sestamibi scan and pertechnetate thyroid scan
with SPECT or SPECT/CT neck
Sestamibi scan and pertechnetate thyroid scan

Usually Appropriate

☢☢☢

Usually Appropriate

☢☢☢

Usually Appropriate

☢☢☢

May Be Appropriate (Disagreement)

☢☢☢

MRI neck with IV contrast

May Be Appropriate

O

MRI neck without and with IV contrast

May Be Appropriate

O

CT neck with IV contrast

May Be Appropriate

☢☢☢

May Be Appropriate (Disagreement)

☢☢☢

Venous sampling parathyroid

Usually Not Appropriate

Varies

MRI neck without IV contrast

Usually Not Appropriate

O

CT neck without IV contrast

Usually Not Appropriate

☢☢☢

Sestamibi scan and I-123 thyroid scan
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Variant 4. Adult or child. Tertiary hyperparathyroidism. Initial imaging.
Procedure

Appropriateness Category

Relative Radiation Level

US parathyroid

Usually Appropriate

O

Sestamibi scan and pertechnetate thyroid scan

Usually Appropriate

☢☢☢

CT neck without and with IV contrast

Usually Appropriate

☢☢☢

Sestamibi dual-phase scan neck

Usually Appropriate

☢☢☢

Sestamibi dual-phase scan with SPECT or SPECT/CT
neck
Sestamibi scan and I-123 thyroid scan with SPECT or
SPECT/CT neck
Sestamibi scan and pertechnetate thyroid scan with
SPECT or SPECT/CT neck
MRI neck with IV contrast

Usually Appropriate

☢☢☢

Usually Appropriate

☢☢☢

Usually Appropriate

☢☢☢

May Be Appropriate

O

MRI neck without and with IV contrast

May Be Appropriate

O

CT neck with IV contrast

May Be Appropriate

☢☢☢

May Be Appropriate (Disagreement)

☢☢☢

Venous sampling parathyroid

Usually Not Appropriate

Varies

MRI neck without IV contrast

Usually Not Appropriate

O

CT neck without IV contrast

Usually Not Appropriate

☢☢☢

Sestamibi scan and I-123 thyroid scan

Table 1. Appropriateness category names and deﬁnitions
Appropriateness Category Name

Appropriateness Rating

Appropriateness Category Deﬁnition

Usually Appropriate

7, 8, or 9

May Be Appropriate

4, 5, or 6

May Be Appropriate (Disagreement)

5

Usually Not Appropriate

1, 2, or 3

The imaging procedure or treatment is
indicated in the speciﬁed clinical scenarios at
a favorable risk-beneﬁt ratio for patients.
The imaging procedure or treatment may be
indicated in the speciﬁed clinical scenarios as
an alternative to imaging procedures or
treatments with a more favorable riskbeneﬁt ratio, or the risk-beneﬁt ratio for
patients is equivocal.
The individual ratings are too dispersed from
the panel median. The different label
provides transparency regarding the panel’s
recommendation. “May be appropriate” is
the rating category and a rating of 5 is
assigned.
The imaging procedure or treatment is unlikely
to be indicated in the speciﬁed clinical
scenarios, or the risk-beneﬁt ratio for
patients is likely to be unfavorable.
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Table 2. Relative radiation level designations
RRL

Adult Effective Dose Estimate Range (mSv)

Pediatric Effective Dose Estimate Range (mSv)

O

0

0

☢

<0.1

<0.03

☢☢

0.1-1

0.03-0.3

☢☢☢

1-10

0.3-3

☢☢☢☢

10-30

3-10

☢☢☢☢☢

30-100

10-30

Note: Relative radiation level (RRL) assignments for some of the examinations cannot be made, because the actual patient doses in these
procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is
used). The RRLs for these examinations are designated as “varies.”

SUMMARY OF LITERATURE REVIEW
Introduction/Background
Hyperparathyroidism is deﬁned as excessive parathyroid
hormone (PTH) production. The most common form,
primary hyperparathyroidism (PHPT), occurs when 1
parathyroid glands autonomously overproduce PTH, typically resulting in hypercalcemia [1]. PHPT is diagnosed by
biochemical testing, speciﬁcally serum calcium and serum
PTH. Usually due to a single parathyroid adenoma (80%),
PHPT can also occur from multiple adenomas, parathyroid
hyperplasia, or, rarely, parathyroid carcinoma (<1%).
Multigland disease (MGD), deﬁned as multiple adenomas
or multiple gland hyperplasia, affects approximately 15% to
20% of patients with PHPT [1,2]. PHPT is more
common in women, with an incidence of 66 per 100,000
person-years, and 25 per 100,000 person-years in men; the
prevalence appears to be increasing signiﬁcantly [3]. Most
cases are sporadic, although hereditary causes exist,
including multiple endocrine neoplasia types 1 and 2A as
well as familial hyperparathyroidism. In countries where
biochemical screening is routine, such as the United
States, Canada, and most of Europe, PHPT predominately
presents as an asymptomatic disorder. Conversely, in
countries where routine biochemical screening is not
commonplace, such as China or India, PHPT predominately
presents with symptoms related to target organ involvement
including: bone demineralization, fractures, nephrolithiasis,
nephrocalcinosis, muscle weakness, or neurocognitive
disorders [1]. Treatment of PHPT is surgical excision of the
abnormally functioning parathyroid tissue and is typically
indicated even when asymptomatic, given potential negative
effects of long-term hypercalcemia [1,2].
There are 2 accepted curative operative strategies for
PHPT: bilateral neck exploration (BNE) and minimally
invasive parathyroidectomy (MIP). BNE refers to a bilateral
S410

operation in which all parathyroid glands are identiﬁed and
examined by the surgeon, who resects the diseased glands.
MIP is deﬁned variably in the literature, for this document,
MIP refers to a unilateral operation utilizing limited
dissection for targeted removal of only the affected gland.
MIP is therefore less invasive than BNE. BNE has traditionally been the standard surgical method of parathyroidectomy and remains the necessary method in cases of
discordant or nonlocalizing preoperative imaging or when
there is high suspicion for MGD [2]. However, because
most patients with PHPT have a single adenoma [2],
directed MIP is often performed as it conveys the beneﬁts
of shorter operating times, faster recovery, and decreased
perioperative costs [4-8]. MIP requires conﬁdent and
precise preoperative localization of a single parathyroid
adenoma to guide the surgical approach; intraoperative
PTH monitoring is used to conﬁrm removal of the
hyperfunctioning gland [2,9]. Therefore, the role of
imaging in PHPT is to localize the abnormally
functioning gland or glands with high accuracy and high
conﬁdence to facilitate targeted curative surgery.
Importantly, imaging has no utility in conﬁrming or
excluding the diagnosis of PHPT [2,8].
Persistent PHPT is deﬁned as failure to achieve normocalcemia within 6 months of initial parathyroidectomy,
whereas recurrent PHPT is deﬁned as hypercalcemia
occurring after a normocalcemic interval of 6 months or
more after parathyroidectomy [2,10]. Parathyroid
reoperations are surgically challenging, with lower cure
rates than ﬁrst-time surgery and higher complication rates.
As such, recent international guidelines state that preoperative imaging is essential in the reoperative setting to localize
a target parathyroid lesion (or lesions) and to identify
postoperative changes from previous parathyroid explorations that can impact a subsequent surgery [10].
Journal of the American College of Radiology
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Secondary hyperparathyroidism (SHPT) is a failure of
calcium homeostasis whereby increased PTH production in
response to hypocalcemia (and/or hyperphosphatemia) is
unable to correct plasma calcium because of organ failure or
reduced calcium availability. This is most commonly due to
chronic kidney disease but can also be a result of malabsorption or vitamin D deﬁciency, among other causes [11].
Rarely, tertiary hyperparathyroidism (THPT) can occur in
patients with long-standing SHPT and is characterized by
a lack of PTH suppression despite rising serum calcium
levels, manifesting as hypercalcemic hyperparathyroidism.
This is most commonly encountered following kidney
transplantation in patients with long-standing chronic
kidney disease [11]. Surgical excision is recommended
for medically refractory cases of SHPT and THPT. As
these are typically disorders of MGD (ie, parathyroid
hyperplasia), the goal of imaging is to identify all eutopic
and potential ectopic or supernumerary glands in an
attempt to guide the surgical approach [10,12-14].

lesion localization with a combination of examinations
over each examination in isolation [12,16-25].

Special Imaging Considerations
For the purposes of parathyroid imaging, CT neck without
and with intravenous (IV) contrast is understood to represent a “4-D parathyroid CT.” Originally described in 2006
[26], this multiphase technique leverages the unique
perfusion characteristics of parathyroid adenomas to
differentiate them from mimics such as exophytic thyroid
nodules and lymph nodes. Variations on the original
4-phase 4-D parathyroid CT technique have since been
described, including 2- [27] and 3-phase [28-33] protocols.
The optimal number of postcontrast phases is undetermined;
however, the most commonly performed method consists of
3 phases: noncontrast, arterial, and venous [34].

DISCUSSION OF PROCEDURES BY VARIANT
Initial Imaging Deﬁnition
Initial imaging is deﬁned as imaging at the beginning of the
care episode for the medical condition deﬁned by the
variant. More than one procedure can be considered usually
appropriate in the initial imaging evaluation when:
n

There are procedures that are equivalent alternatives (ie,
only one procedure will be ordered to provide the clinical
information to effectively manage the patient’s care)
OR

n

There are complementary procedures (ie, more than one
procedure is ordered as a set or simultaneously in which
each procedure provides unique clinical information to
effectively manage the patient’s care).

There is no universally accepted algorithm for parathyroid imaging. As detailed in the following variants, there
is much variability in the reported sensitivities for imaging
modalities, with no single technique shown to be clearly
superior in localizing parathyroid lesions in all patients. The
selection of an initial imaging study should be made with
consideration for surgeon and radiologist preference,
regional expertise, and characteristics unique to each patient’s presentation (eg, suspicion for MGD, underlying
hereditary cause, concomitant thyroid disease, etc). Multiple
imaging modalities may be utilized in combination during
the initial imaging evaluation in an attempt to maximize the
accuracy and conﬁdence of parathyroid localization via
concordant imaging results [2,8,10,15]. This is supported
by various studies in the literature showing improved
sensitivity and positive predictive value (PPV) in parathyroid
Journal of the American College of Radiology
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Variant 1: Adult or child. Primary
hyperparathyroidism. Initial imaging
All patients undergoing imaging in the setting of PHPT
should have biochemically proven disease, as imaging has no
role in conﬁrming or excluding the diagnosis [2]. As such,
assessing the imaging test speciﬁcity and negative
predictive value is not clinically relevant. Rather, the role
of initial imaging in PHPT is to aid in selecting
appropriate patients for MIP by accurately identifying and
localizing a single parathyroid adenoma; accordingly, these
criteria focus on imaging test sensitivity and PPV. Patients
with negative or inconclusive imaging results typically
remain surgical candidates but will likely require BNE;
inconclusive ﬁndings on imaging should not preclude
surgical referral [2].
Multiple imaging modalities may be utilized in combination during the initial imaging evaluation of PHPT in an
attempt to maximize the accuracy and conﬁdence of parathyroid localization via concordant imaging results [2,8,15].
This is supported by multiple studies in the literature
showing improved sensitivity and PPV in parathyroid
lesion localization with a combination of examinations
over each examination in isolation [16-23,25].

CT Neck. Neck CT for preoperative localization of PHPT
is most commonly performed without and with IV contrast
(4-D parathyroid CT) [34]. As such, most published data
relate to the performance of CT neck without and with
IV contrast; however, there are also some data on the
performance of CT neck with IV contrast. There is no
relevant literature regarding the use of CT neck without
IV contrast in the evaluation of PHPT.
S411

As the initial imaging study, retrospective studies report
the overall sensitivity of CT neck without and with IV
contrast to range between 62% and 88% [35,36] and the
overall PPV to range between 84% and 90% [32,37]. The
largest retrospective study (400 patients) reports an overall
sensitivity of 79% and PPV of 90% [32]. For single-gland
disease, reported sensitivities and PPVs range from 92% to
94% [30,38] and 88% to 92% [38,39], respectively. For
MGD, reported sensitivities and PPVs range from 43% to
67% [39,40] and 89% to 100%, respectively [32,39].
A data-driven rationale for the noncontrast CT phase
has been provided (eg, differentiation of parathyroid from
thyroid tissue): 22% of parathyroid lesions have an
enhancement pattern similar to thyroid on arterial and
venous phases and therefore may be missed if the noncontrast phase were excluded [30]. However, a few
retrospective reports suggest that eliminating the
noncontrast CT phase may not adversely affect test
performance [41-43]. The largest retrospective study (278
patients) of CT neck with IV contrast (without the
noncontrast phase) reports sensitivity of 55% and PPV of
57% among patients with single-gland disease, and sensitivity of 23% and PPV of 19% among patients with MGD
[44].
Several studies have directly compared the performance
of neck CT without and with IV contrast to ultrasound
(US) and to nuclear medicine scans within the same patient
population. Most of these studies found the performance of
neck CT without and with IV contrast to be superior
[29,31,38,40]; however, a prospective study of 91 patients
found neck CT without and with IV contrast (58%
sensitivity, 88% PPV) to be inferior to dual isotope
(sestamibi and I-123) pinhole subtraction scintigraphy
(93% sensitivity, 98% PPV) [45].

MRI Neck. MRI neck is an emerging technique for PHPT
preoperative localization and may be performed without IV
contrast, with IV contrast, or without and with IV contrast.
Most studies evaluating the performance of MRI neck for
preoperative localization in the setting of PHPT are retrospective and include fewer than 50 patients.
As the initial imaging study, the sensitivity of MRI neck
without and with IV contrast performed at 1.5T has been
reported to be between 64% and 79% [46-48]. In 2
prospective studies performed at 3.0T, the sensitivity of
MRI neck without and with IV contrast ranged between
64% and 98%, and the PPV ranged between 67% and
95% [49,50]. A third prospective study of MRI without
and with IV contrast performed at 3.0T reported accurate
localization of parathyroid adenomas in 92% (34/37) of
patients with single-gland disease and 74% (35/47) of patients with MGD [51]. For MRI without IV contrast, the
S412

reported sensitivity was 67% at 1.5T [52]. There is no
relevant literature regarding the use of 3.0T MRI without
IV contrast in the initial imaging evaluation of PHPT.

Sestamibi Dual-Phase Scan Neck. Dual-phase Tc-99m
sestamibi planar parathyroid scintigraphy is an accepted
and traditionally widely utilized method for parathyroid
adenoma localization in PHPT. The sensitivity of this
method (typically reported as localization to the correct
quadrant or to an ectopic location) varies widely in the
literature, ranging from 41% to 96% [45,52-63]. A larger
retrospective study of 180 patients reported a sensitivity of
79% [58]. A systematic review of 11 studies reported a
pooled sensitivity of 76% [17]. Some variability in these
results may arise from varied technical parameters of these
scans (eg, timing of early and delayed scans, use of
pinhole versus parallel collimators, addition of oblique
acquisitions, etc).
There is no clear consensus regarding the superiority
between sestamibi dual-phase and dual-tracer subtraction
planar imaging. One recent study of 63 patients showed
greater sensitivity with dual-phase sestamibi (79%) over
both dual-tracer (sestamibi and pertechnetate) (69%) and a
combined dual-tracer/dual-phase technique (65%) [59].
However, other studies report similar or improved
sensitivity of dual-tracer methods (either pertechnetate or
I-123, plus sestamibi) over dual-phase sestamibi when utilizing a planar technique [45,54,64,65]. There is a growing
consensus that the addition of single-photon emission CT
(SPECT) without or with a coregistered CT (SPECT/CT)
improves localization of parathyroid adenomas over a planar
dual-phase sestamibi method [59,61,62].
The sensitivity of sestamibi imaging is decreased in the
setting of MGD [55,58], concomitant nodular thyroid
disease [56,66], small adenomas [53], and mild
hypercalcemia [58].
Literature regarding the pediatric population is limited.
A retrospective review of 29 patients reported that sestamibi
was useful only in older children with a single adenoma in
the setting of sporadic PHPT, and added minimal additional information compared with US, with otherwise no
utility for sestamibi in neonates or familial PHPT [67].
Sestamibi Dual-Phase Scan With SPECT or SPECT/
CT Neck. The addition of SPECT or SPECT/CT to a
dual-phase sestamibi scan is more commonly utilized than
planar imaging alone. Although there are a number of variations in the timing of the SPECT or SPECT/CT acquisition (ie, early, delayed, or both), it is generally accepted
that the improved contrast resolution of SPECT or SPECT/
CT over planar imaging provides more precise anatomic
localization of parathyroid adenomas [68,69].
Journal of the American College of Radiology
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Reported sensitivities of sestamibi dual-phase scan with
SPECT or SPECT/CT range from 67% to 86%.
n

n

n

n

Thomas et al: In a study of patients with parathyroid
adenomas and parathyroid hyperplasia, direct comparison
of dual-phase sestamibi planar imaging to dual-phase
sestamibi with SPECT showed improved sensitivities
from 42% to 67%, respectively; this includes detection of
parathyroid hyperplasia by SPECT, which was missed by
planar imaging [61].
Cheung et al: A meta-analysis of 7 studies found a pooled
sensitivity of 79% and a pooled PPV of 91% for dualphase sestamibi with SPECT [70].
Wong et al: A meta-analysis of 24 studies found a pooled
sensitivity of 86% for dual-phase sestamibi with SPECT/
CT compared with 74% for sestamibi with SPECT and
70% for sestamibi planar alone [62].
Yeh et al: A study of 400 patients reported a sensitivity of
58% and PPV of 96% for sestamibi with SPECT/CT. A
combined method of sestamibi with SPECT/CT plus
4-D parathyroid CT yielded a sensitivity of 80%, which
was not substantially different than 4-D parathyroid CT
alone at 79% [32].

The sensitivity of dual-phase sestamibi with SPECT or
SPECT/CT is decreased by MGD, uptake masked by
retained radionuclide in adjacent thyroid or submandibular
gland tissue, and smaller size of the adenoma (within these
subsets, sensitivity ranges from 24% to 66%) [71-73].

Sestamibi Scan and I-123 Thyroid Scan. Subtraction
scintigraphy of parathyroid glands using a combination of
sestamibi and I-123 sodium iodide is a commonly utilized
alternative or adjunct to the dual-phase sestamibi technique.
The 2009 European Association of Nuclear Medicine
parathyroid guidelines expressed a preference for the dualtracer sestamibi and I-123 technique, citing improved
sensitivity for MGD and improved likelihood of distinguishing sestamibi-avid thyroid nodules from parathyroid
lesions [15]. A major technical advantage of using I-123 for
a subtraction technique is that thyroid and parathyroid
images can be acquired simultaneously in a dual-energy
window.
Reported sensitivity for dual-tracer sestamibi and I-123
subtraction scintigraphy ranges from 75% to 94% [54,7476], including a retrospective review of 2,681 patients
revealing a sensitivity of 87% and PPV of 92% [77]. The
latter study showed that negative or inconclusive results
had a higher association with MGD and lower serum
calcium levels.
There is no clear consensus regarding the superiority
between dual-tracer subtraction and sestamibi dual-phase
planar imaging. One recent study of 63 patients showed
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greater sensitivity with dual-phase sestamibi (79%) over
both dual-tracer (sestamibi and pertechnetate) (69%) and a
combined dual-tracer/dual-phase (65%) technique [59].
However, other studies report similar or improved
sensitivity of dual-tracer methods (either pertechnetate or
I-123, plus sestamibi) over dual-phase sestamibi when utilizing a planar technique [45,54,64,65].

Sestamibi Scan and I-123 Thyroid Scan With SPECT
or SPECT/CT Neck. Although there are a number of
variations in the timing of the SPECT or SPECT/CT
acquisition (ie, early, delayed, or both), it is generally
accepted that the improved contrast resolution of SPECT or
SPECT/CT over planar imaging provides more precise
anatomic localization of parathyroid adenomas [68,69].
However, there are conﬂicting data in the literature as to
what extent the addition of SPECT or SPECT/CT
changes the sensitivity of the examination. For example,
Bhatt et al [74] evaluated a pinhole protocol, SPECT/CT
alone, and a combination of pinhole/SPECT/CT, revealing
sensitivities of 88%, 69%, and 81%, respectively. Other
studies have shown superior performance of the combined
sestamibi/I-123 plus SPECT/CT protocol with sensitivities
ranging from 86% to 95% and PPV from 86% to 100%
[45,75,78,79].
The sensitivity and PPV of a sestamibi/I-123 subtraction technique are least negatively impacted by concomitant
thyroid disease when SPECT/CT is included in the protocol
[75].
Sestamibi Scan and Pertechnetate Thyroid Scan. Subtraction scintigraphy of parathyroid glands using a combination of sestamibi and Tc-99m pertechnetate is a commonly
utilized alternative or adjunct to the dual-phase sestamibi
technique. Unlike the dual-tracer method with I-123, the
pertechnetate method requires 2 separate acquisitions, which
prolongs the overall examination time. Although techniques
based solely on planar imaging have largely been supplanted
by methods with SPECT or SPECT/CT, there are some
noteworthy applications of a planar sestamibi and pertechnetate subtraction in recent literature with reported sensitivities ranging from 69% to 79% [59,80]. A meta-analysis
including 5 studies utilizing a dual-tracer technique reported
sensitivities ranging from 47% to 87%; however, it is unclear
which studies relied purely on a subtracted dual-tracer (sestamibi and pertechnetate) planar method and which were
performed in combination with a dual-phase sestamibi scan
[17]. In a study of 116 patients with PHPT, the addition of
pertechnetate subtraction to a dual-phase sestamibi scan
increased reader conﬁdence in adenoma localization and
changed the ﬁnal interpretation in 15% of patients from the
dual-phase study [81].
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MGD decreases the sensitivity of the subtraction sestamibi and pertechnetate scan from 71% to 64% [82].
There is no clear consensus regarding the superiority
between dual-tracer subtraction and sestamibi dual-phase
planar imaging. One recent study of 63 patients showed
greater sensitivity with dual-phase sestamibi (79%) over
both dual-tracer (sestamibi and pertechnetate) (69%) and a
combined dual-tracer/dual-phase technique (65%) [59].
However, other studies report similar or improved
sensitivity of dual-tracer methods (either pertechnetate or
I-123, plus sestamibi) over dual-phase sestamibi when utilizing a planar technique [45,54,64,65].

Sestamibi Scan and Pertechnetate Thyroid Scan With
SPECT or SPECT/CT Neck. Although there are a
number of variations in the timing of the SPECT or
SPECT/CT acquisition (ie, early, delayed, or both), it is
generally accepted that the greater contrast resolution of
SPECT or SPECT/CT over planar imaging provides more
precise anatomic localization of parathyroid adenomas
[68,69]. The addition of a pertechnetate thyroid scan may
further improve localization: in a study of 268 patients,
planar pertechnetate subtraction in combination with a
dual-phase sestamibi scan with SPECT/CT outperformed
the dual-phase sestamibi SPECT/CT alone, increasing
sensitivity to 93% and PPV to 96% compared with 88%
and 92%, respectively [83].
In patients with concomitant thyroid disease, the
addition of CT to a dual-tracer sestamibi and pertechnetate SPECT scan increases sensitivity from 80% to 94%
[84].
US Parathyroid. US of the parathyroid glands is widely
utilized as the initial imaging study in PHPT. Both the
American Head and Neck Society Endocrine Surgery Section and the American Association of Endocrine Surgeons
deem US to be the preferred initial localization study in
patients with PHPT, noting the advantage of concomitant
thyroid evaluation [2,8]. A 2012 meta-analysis of 19 studies
evaluating US in patients with PHPT revealed a pooled
sensitivity of 76% and PPV of 93% [70]. A subsequent
2017 meta-analysis of 12 studies (with few studies also
included from the 2012 meta-analysis) revealed a pooled
sensitivity of 80% [85]. However, the range of sensitivities
reported in the literature varies widely. For example, a
study of 604 patients comparing US, scintigraphy, and 4D CT reported a sensitivity of 59% for US [31], with
other smaller studies reporting US sensitivities ranging
from 44% to 97% [18,20,58,86-90].
Nonlocalizable adenomas by US are most often due to
ectopic or far posterior location, MGD, small adenoma size,
and concomitant thyroid disease [58,86,91].
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The literature in the pediatric population is limited. In a
retrospective review of 29 patients, Alagaratnam et al [67]
reported that US in 2 neonates resulted in false-negatives;
sensitivity improved in older children to 93%. In a separate study of 16 children, sensitivity of US was 60% [7].

Venous Sampling Parathyroid. Parathyroid glands tend
to drain ipsilaterally and inferiorly relative to their anatomic
location. As such, sampling of PTH levels during selective
transvenous catheterization of multiple neck and mediastinal
veins can be used to infer the laterality and regional location
of parathyroid lesions [8,92,93]. Direct differential jugular
venous sampling of PTH to infer laterality of an adenoma
in patients with PHPT has also been described in the
literature but is beyond the scope of this document
[94,95]. Because of its invasive technique, selective
parathyroid venous sampling is typically reserved for
reoperative surgical candidates with recurrent or persistent
PHPT after noninvasive examinations (eg, US, sestamibi,
CT, etc) yield nonlocalizing, equivocal, or discordant
results [96]. Otherwise, there are limited data regarding
the use of selective venous sampling for parathyroid
localization as the initial examination for PHPT in the
surgically naïve patient. Hader et al [92] in a study of 23
patients from Germany underwent parathyroidectomy for
hyperparathyroidism, 8 of which as their initial surgery,
and results of selective parathyroid venous sampling were
retrospectively reviewed. Across the entire cohort, the
reported sensitivity was 94% and PPV was 89%.

Variant 2: Adult or child. Primary
hyperparathyroidism, recurrent or persistent
after parathyroid surgery. Initial imaging
All patients undergoing imaging in the setting of recurrent
or persistent PHPT should have biochemically proven disease, as imaging has no role in conﬁrming or excluding the
diagnosis [2,10]. As such, assessing the imaging test
speciﬁcity and negative predictive value is not clinically
relevant. Rather, the role of initial imaging in recurrent or
persistent PHPT is to accurately identify and localize a
parathyroid lesion (or lesions) and identify postoperative
changes from previous parathyroid explorations, which can
impact a subsequent surgery. Accordingly, these criteria
focus on imaging test sensitivity and PPV.
Multiple imaging modalities may be utilized in combination during the initial imaging evaluation of recurrent or
persistent PHPT after prior surgery in an attempt to
maximize the accuracy and conﬁdence of parathyroid
localization via concordant imaging results [10,15].

CT Neck. Neck CT in the evaluation of recurrent or
persistent PHPT after prior surgery is most commonly
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performed without and with IV contrast (4-D parathyroid
CT) [34], which is reﬂected in the published data regarding
the performance of neck CT for parathyroid localization in
the setting of prior failed surgery. There is no literature
regarding the use of CT neck with IV contrast speciﬁcally
limited to patients with recurrent or persistent PHPT.
Additionally, there is no relevant literature regarding the
use of CT neck without IV contrast in the evaluation of
PHPT.
In the setting of recurrent or persistent PHPT, retrospective studies report the sensitivity of CT neck without
and with IV contrast to range between 50% and 91% and
the PPV to range between 69% and 100% [29,36,40,97].

MRI Neck. Neck MRI is an emerging technique in the
evaluation of recurrent or persistent PHPT after prior surgery. There are limited data regarding the use of MRI neck
without and with IV contrast in the setting of prior surgery:
n

n

Aschenbach et al: 30 patients from Germany underwent
reoperative parathyroidectomy for PHPT, and results of
MRI performed prior to reoperation were retrospectively
reviewed. Using only conventional MRI sequences (without
and with IV contrast), the sensitivity was 63%, and the PPV
was 100%. With the addition of dynamic sequences, the
sensitivity was 93%, and the PPV was 100% [98].
Kluijfhout et al: 84 patients from California underwent
reoperative parathyroidectomy for persistent PHPT, and
results of MRI performed prior to reoperation were
retrospectively reviewed. The sensitivity of MRI neck
without and with IV contrast was 82%, and the PPV was
85%. The sensitivity and PPV of dynamic sequences were
both 90% [48].

There is no relevant literature regarding the use of MRI
without IV contrast in the evaluation of recurrent or
persistent PHPT.

Sestamibi Dual-Phase Scan Neck. There is no relevant
literature regarding the use of planar sestamibi dual-phase
scans in the evaluation of recurrent or persistent PHPT after prior surgery.
Sestamibi Dual-Phase Scan With SPECT or SPECT/
CT Neck. There are limited data regarding the use of
sestamibi dual-phase scans with SPECT or SPECT/CT in
the setting of prior surgery:
n

Kluijfhout et al: 84 patients from California underwent
reoperative parathyroidectomy for persistent PHPT, and
results of sestamibi scans with SPECT/CT performed prior
to reoperation were retrospectively reviewed. The reported
sensitivity was 74%, and the PPV was 86% [48].

Journal of the American College of Radiology
Zander et al n Parathyroid Adenoma

n

Witteveen et al: 19 patients from The Netherlands underwent reoperative parathyroidectomy for persistent
PHPT. Results of sestamibi scans with SPECT performed prior to reoperation were retrospectively reviewed
and compared with a 23-patient cohort undergoing the
same preoperative imaging for surgically naïve sporadic
PHPT. For patients with persistent PHPT, the sensitivity
for localizing parathyroid glands on a per-lesion basis was
33% as compared with 61% for the cohort imaged prior
to their initial surgery [99].

Sestamibi Scan and I-123 Thyroid Scan. There is no
relevant literature regarding the use of planar sestamibi and
I-123 scans in the evaluation of recurrent or persistent
PHPT after prior surgery.
Sestamibi Scan and I-123 Thyroid Scan With SPECT
or SPECT/CT Neck. There are limited data regarding the
use of sestamibi and I-123 scans with SPECT or SPECT/
CT in the setting of recurrent or persistent PHPT after prior
surgery:
n

Shin et al: 176 patients from Ohio underwent reoperative
parathyroidectomy for recurrent or persistent hyperparathyroidism, including patients with PHPT, SHPT, and
THPT. Results of sestamibi and I-123 scans with SPECT
(103 patients) and sestamibi and I-123 scans with
SPECT/CT (73 patients) performed prior to reoperation
were retrospectively reviewed. Reported sensitivities were
74% and 86%, respectively [100].

Sestamibi Scan and Pertechnetate Thyroid Scan. There
is no relevant literature regarding the use of planar sestamibi
and pertechnetate scans in the evaluation of recurrent or
persistent PHPT after prior surgery.
Sestamibi Scan and Pertechnetate Thyroid Scan With
SPECT or SPECT/CT Neck. There is no relevant literature regarding the use of sestamibi and pertechnetate scans
with SPECT or SPECT/CT in the evaluation of recurrent
or persistent PHPT after prior surgery.
US Parathyroid. A 2017 joint consensus statement of the
American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons recommends US as
a ﬁrst-line imaging examination in the reoperative setting,
citing the added advantage of revealing nodular thyroid
disease, lymphadenopathy, and postoperative changes from
the previous parathyroid exploration [10]. Otherwise, there
are limited data within the last 10 years regarding the use of
US in the setting of recurrent or persistent hyperparathyroidism
after prior surgery:
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Hamidi et al: 58 patients from Massachusetts underwent
reoperative parathyroidectomy for recurrent or persistent
PHPT and results of US performed prior to reoperation
were retrospectively reviewed. An examination was
considered a true-positive if it identiﬁed the correct laterality (compared to quadrant or region). The reported
sensitivity on a per-lesion basis (62 lesions) was 46% [101].
Kluijfhout et al: 84 patients from California underwent
reoperative parathyroidectomy for persistent PHPT, and
the results of US performed prior to reoperation were
retrospectively reviewed. The reported sensitivity was
54%, and the PPV was 71% [48].
Shin et al: 176 patients from Ohio underwent reoperative
parathyroidectomy for recurrent or persistent hyperparathyroidism, including patients with PHPT, SHPT, and
THPT. Results of US performed prior to reoperation
were retrospectively reviewed, with reported sensitivity of
69% [100].

Venous Sampling Parathyroid. Parathyroid glands tend
to drain ipsilaterally and inferiorly relative to their anatomic
location. As such, sampling of PTH levels during selective
transvenous catheterization of multiple neck and mediastinal
veins can be used to infer the laterality and regional location
of parathyroid lesions [8,92,93]. Because of its invasive
technique, selective parathyroid venous sampling is typically
reserved for reoperative surgical candidates with recurrent or
persistent PHPT after noninvasive examinations (eg, US,
sestamibi, CT, etc) yield nonlocalizing, equivocal, or
discordant results [96,102].
Although parathyroid venous sampling has been in use
since the 1990s [102], there are few pertinent studies within
the last 10 years, and nearly all evaluate patients who have
had prior nonlocalizing examinations, as this is the subset
of patients for whom this examination is typically
reserved. These studies are retrospective and each
evaluated fewer than 40 patients, reporting sensitivities
ranging from 40% to 93% [92,93,97,103-105].
There is a potential for false regionalization and/or
lateralization of parathyroid lesions due to congenitally
variant venous anatomy or alteration of regional venous
drainage secondary to previous surgical interventions [93].
As with many invasive vascular procedures, venous
sampling is potentially associated with serious but
uncommon complications [10].

Variant 3: Adult or child. Secondary
hyperparathyroidism. Initial imaging
All patients undergoing imaging in the setting of SHPT should
have biochemically proven disease, as imaging has no role in
conﬁrming or excluding the diagnosis [11]. As such, assessing
the imaging test speciﬁcity and negative predictive value is not
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clinically relevant. Rather, as SHPT is typically a disorder of
MGD and is therefore treated with BNE, the role of initial
imaging is to accurately identify all eutopic and potential
ectopic or supernumerary glands in an attempt to decrease
surgical failure rates [12-14]; accordingly, these criteria focus
on imaging test sensitivity and PPV.
It is possible that multiple imaging modalities may be
utilized in combination during the initial imaging evaluation of SHPT in an attempt to maximize the accuracy and
conﬁdence of parathyroid localization via concordant imaging results. This is supported by limited literature speciﬁc to SHPT [12] and otherwise inferred from data
regarding PHPT [16-23] showing improved sensitivity
and PPV in parathyroid lesion localization with a
combination of examinations over each examination in
isolation.

CT Neck. There are limited data regarding the use of CT
neck for localization in SHPT:
n

n

Lee et al: 109 patients from Korea underwent parathyroidectomy for refractory SHPT, and results of preoperative localization studies were retrospectively
reviewed. The reported sensitivity of CT neck was 85%,
although details related to the CT acquisition (ie, without
IV contrast, with IV contrast, or without and with IV
contrast) are not provided; furthermore, the overall
incidence of reported ectopic glands was much lower than
typical at 1%, with all ectopic glands missed by CT
[106].
Hiramitsu et al: 291 patients from Japan underwent
parathyroidectomy for SHPT, and results of preoperative
localization studies were retrospectively reviewed. The
reported sensitivity of CT neck was 60%, and the PPV
was 100%. Details related to the CT acquisition are not
provided [107].

MRI Neck. There is no relevant literature regarding the
use of MRI neck performed without IV contrast, with IV
contrast, or without and with IV contrast in the evaluation
of SHPT.
Sestamibi Dual-Phase Scan Neck. There are limited
data regarding the use of planar sestamibi dual-phase scans
in the evaluation of SHPT:
n

Vulpio et al: 21 patients from Italy underwent parathyroidectomy for SHPT, and the results of preoperative
sestamibi scans were retrospectively reviewed. The reported sensitivity on a per-lesion basis was 62% [12].

Sestamibi Dual-Phase Scan With SPECT or SPECT/
CT Neck. There are limited data regarding the use of
sestamibi dual-phase scans with SPECT or SPECT/CT in
the evaluation of SHPT:
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Yang et al: 80 patients from China with SHPT on hemodialysis underwent parathyroidectomy and results of
preoperative sestamibi scans with SPECT/CT were
retrospectively reviewed. The reported sensitivity was
85% on a per-patient basis [108].
Li et al: 50 patients from China with SHPT underwent
parathyroidectomy and results of preoperative sestamibi
scans with SPECT/CT were retrospectively reviewed.
The reported sensitivity was 59% on a per-lesion basis
(out of 183 hyperplastic parathyroid glands) [109].
Karipineni et al: This is the largest and most comprehensive study, a retrospective review of 2,975 patients
from Maryland from 2004 to 2015. The aim of the study
was to evaluate whether preoperative imaging could
reliably identify ectopic glands in patients expected to
have MGD. As such, the study was not limited to patients with SHPT but also included patients with THPT,
lithium-induced PHPT, and PHPT due to multiple
endocrine neoplasia; patients with SHPT comprised 55%
of the cohort. On a per-lesion basis, the reported sensitivity of sestamibi dual-phase scans with SPECT in
detecting ectopic glands was 29% [110].

Sestamibi Scan and I-123 Thyroid Scan. There is no
relevant literature regarding the use of planar sestamibi scan
and I-123 thyroid scan in the evaluation of SHPT.
Sestamibi Scan and I-123 Thyroid Scan With SPECT
or SPECT/CT Neck. There are limited data regarding the
use of sestamibi scan and I-123 thyroid scan with SPECT or
SPECT/CT in the evaluation of SHPT:
n

studies evaluating the sensitivity of US on a per-lesion basis,
inclusive of both eutopic and ectopic locations, report sensitivities ranging from 46% to 94% [12,85,111,112].
Although localization of eutopic glands is useful, the
identiﬁcation and localization of ectopic and supernumerary
glands is paramount to decreasing failure rates of BNE:
n

n

n

Alkhalili et al: 103 patients from New Mexico with either
SHPT (34%) or THPT (66%) underwent parathyroidectomy and results of preoperative localization
were retrospectively reviewed. The reported sensitivity for
ectopic glands on a per-lesion basis by US was 32% [14].
Andrade et al: 166 patients from Brazil with either SHPT
(27%) or THPT (73%) underwent parathyroidectomy
and results of preoperative localization were retrospectively reviewed. The reported sensitivity for ectopic
glands on a per-lesion basis by US was 20% [13].
Karipineni et al: This is the largest and most comprehensive study, a retrospective review of 2,975 patients
from Maryland from 2004 to 2015. The aim of the study
was to evaluate whether preoperative imaging could
reliably identify ectopic glands in patients expected to
have MGD. As such, the study was not limited to patients with SHPT but also included patients with THPT,
lithium-induced PHPT, and PHPT due to multiple
endocrine neoplasia; patients with SHPT comprised 55%
of the cohort. On a per-lesion basis, exclusive of ectopic
glands in the mediastinum (which were not included due
to the assumption that US could not adequately image
the mediastinum), the reported sensitivity of US in
detecting ectopic glands was 7% [110].

Alkhalili et al: 103 patients from the United States with
either SHPT or THPT underwent parathyroidectomy
and results of preoperative localization were retrospectively reviewed. The reported sensitivity for ectopic
glands on a per-lesion basis by sestamibi and I-123 scan
with SPECT was 36% [14].

Venous Sampling Parathyroid. There is no relevant
literature regarding the use of venous sampling in the evaluation of SHPT.

Sestamibi Scan and Pertechnetate Thyroid Scan. There
is no relevant literature regarding the use of planar sestamibi
scan and pertechnetate thyroid scan in the evaluation of
SHPT.

All patients undergoing imaging in the setting of THPT
should have biochemically proven disease, as imaging has no
role in conﬁrming or excluding the diagnosis [11]. As such,
assessing the imaging test speciﬁcity and negative predictive
value is not clinically relevant. THPT is typically a disorder
of MGD in which the role of initial imaging is to accurately
identify all eutopic and potential ectopic or supernumerary
glands in an attempt to guide the surgical approach [1214]; accordingly, these criteria focus on imaging test
sensitivity and PPV.
It is possible that multiple imaging modalities may be
utilized in combination during the initial imaging evaluation
of THPT in an attempt to maximize the accuracy and
conﬁdence of parathyroid via concordant imaging results.

Sestamibi Scan and Pertechnetate Thyroid Scan With
SPECT or SPECT/CT Neck. There is no relevant literature regarding the use of sestamibi scan and pertechnetate
thyroid scan with SPECT or SPECT/CT in the evaluation
of SHPT.
US Parathyroid. When utilized as an initial imaging study
in SHPT, US conveys additional beneﬁts of concomitant
evaluation of the thyroid gland. Studies evaluating the use of
US in patients with SHPT vary in their design. Those
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Variant 4: Adult or child. Tertiary
hyperparathyroidism. Initial imaging
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This is inferred from data regarding PHPT [16-23] and
SHPT [12] showing improved sensitivity and PPV in
parathyroid lesion localization with a combination of
examinations over each examination in isolation.

evaluation of the thyroid gland. There are limited data
regarding the use of US in the evaluation of THPT:
n

CT Neck. There is no relevant literature regarding the use
of CT neck in the evaluation of THPT.
MRI Neck. There is no relevant literature regarding the use
of MRI neck performed without IV contrast, with IV contrast,
or without and with IV contrast in the evaluation of THPT.
Sestamibi Dual-Phase Scan Neck. There is no relevant
literature regarding the use of planar sestamibi dual-phase
scan neck in the evaluation of THPT.

n

n

Sestamibi Dual-Phase Scan With SPECT or SPECT/
CT Neck. There are limited data regarding the use of
sestamibi dual-phase scans with SPECT or SPECT/CT in
the evaluation of THPT:
n

Karipineni et al: This is the largest and most comprehensive study, a retrospective review of 2,975 patients
from Maryland from 2004 to 2015. The aim of the study
was to evaluate whether preoperative imaging could
reliably identify ectopic glands in patients expected to
have MGD. As such, the study was not limited to patients with THPT but also included patients with SHPT,
lithium-induced PHPT, and PHPT due to multiple
endocrine neoplasia; patients with THPT comprised
21% of the cohort. On a per-lesion basis, the reported
sensitivity of sestamibi dual-phase scans with SPECT in
detecting ectopic glands was 29% [110].

Sestamibi Scan and I-123 Thyroid Scan. There is no
relevant literature regarding the use of planar sestamibi scan
and I-123 thyroid scan in the evaluation of THPT.
Sestamibi Scan and I-123 Thyroid Scan With SPECT
or SPECT/CT Neck. There is no relevant literature
regarding the use of sestamibi scan and I-123 thyroid scan
with SPECT or SPECT/CT in the evaluation of THPT.
Sestamibi Scan and Pertechnetate Thyroid Scan. There
is no relevant literature regarding the use of planar sestamibi
scan and pertechnetate thyroid scan in the evaluation of
THPT.
Sestamibi Scan and Pertechnetate Thyroid Scan With
SPECT or SPECT/CT Neck. There is no relevant literature regarding the use of sestamibi scan and pertechnetate
thyroid scan with SPECT or SPECT/CT in the evaluation
of THPT.
US Parathyroid. When utilized as an initial imaging study
in THPT, US conveys additional beneﬁts of concomitant
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Alkhalili et al: 103 patients from New Mexico with either
SHPT (34%) or THPT (66%) underwent parathyroidectomy and results of preoperative localization
were retrospectively reviewed. The reported sensitivity for
ectopic glands on a per-lesion basis by US was 32% [14].
Andrade et al: 166 patients from Brazil with either SHPT
(27%) or THPT (73%) underwent parathyroidectomy
and results of preoperative localization were retrospectively reviewed. The reported sensitivity for ectopic
glands on a per-lesion basis by US was 20% [13].
Karipineni et al: This is the largest and most comprehensive study, a retrospective review of 2,975 patients
from Maryland from 2004 to 2015. The aim of the study
was to evaluate whether preoperative imaging could
reliably identify ectopic glands in patients expected to
have MGD. As such, the study was not limited to patients with SHPT but also included patients with THPT,
lithium-induced PHPT, and PHPT due to multiple
endocrine neoplasia; patients with SHPT comprised 55%
of the cohort. On a per-lesion basis, exclusive of ectopic
glands in the mediastinum (which were not included
because of the assumption that US could not adequately
image the mediastinum), the reported sensitivity of US in
detecting ectopic glands was 7% [110].

Venous Sampling Parathyroid. Because of its invasive
technique, selective parathyroid venous sampling is typically
reserved for reoperative surgical candidates with recurrent or
persistent PHPT after noninvasive examinations (eg, US,
sestamibi, CT, etc) yield nonlocalizing, equivocal, or
discordant results [96]. Otherwise, there are limited data
regarding the use of selective venous sampling in the
initial evaluation of THPT:
n

Witteveen et al: 20 patients from The Netherlands underwent parathyroidectomy for hyperparathyroidism,
including 8 patients with THPT, and results of selective
parathyroid venous sampling were retrospectively
reviewed. Across the entire cohort, the reported sensitivity
was 75% [93].

SUMMARY OF RECOMMENDATIONS
n Variant

1: US parathyroid or CT neck without and
with IV contrast or sestamibi dual-phase scan neck or
sestamibi dual-phase scan with SPECT or SPECT/CT
neck or sestamibi scan and I-123 thyroid scan or sestamibi scan and I-123 thyroid scan with SPECT or
SPECT/CT neck or sestamibi scan and pertechnetate
thyroid scan or sestamibi scan and pertechnetate
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thyroid scan with SPECT or SPECT/CT neck is
usually appropriate as the initial imaging of all patients
with PHPT. These procedures are typically equivalent
alternatives (ie, only 1 procedure will be ordered to
provide the clinical information to effectively manage
the patient’s care), although they may be used in a
complementary manner to maximize the accuracy and
conﬁdence of parathyroid localization via concordant
imaging results.
n Variant

2: US parathyroid or CT neck without and
with IV contrast or sestamibi dual-phase scan neck or
sestamibi dual-phase scan with SPECT or SPECT/CT
neck or sestamibi scan and I-123 thyroid scan or sestamibi scan and I-123 thyroid scan with SPECT or
SPECT/CT neck or sestamibi scan and pertechnetate
thyroid scan or sestamibi scan and pertechnetate thyroid scan with SPECT or SPECT/CT neck is usually
appropriate as the initial imaging of all patients with
recurrent or persistent PHPT after parathyroid surgery.
These procedures are typically equivalent alternatives
(ie, only 1 procedure will be ordered to provide the
clinical information to effectively manage the patient’s
care), although they may be used in a complementary
manner to maximize the accuracy and conﬁdence of
parathyroid localization via concordant imaging results.

n Variant

3: US parathyroid or CT neck without and
with IV contrast or sestamibi dual-phase scan neck or
sestamibi dual-phase scan with SPECT or SPECT/CT
neck or sestamibi scan and I-123 thyroid scan with
SPECT or SPECT/CT neck or sestamibi scan and
pertechnetate thyroid scan with SPECT or SPECT/CT
neck is usually appropriate as the initial imaging of all
patients with secondary hyperparathyroidism. These
procedures are typically equivalent alternatives (ie, only
1 procedure will be ordered to provide the clinical information to effectively manage the patient’s care),
although they may be used in a complementary
manner to maximize the accuracy and conﬁdence of
parathyroid localization via concordant imaging results.
The panel did not agree on recommending sestamibi
scan and pertechnetate thyroid scan or sestamibi scan
and I-123 thyroid scan for this clinical scenario. There
is insufﬁcient medical literature to conclude whether
or not these patients would beneﬁt from sestamibi
scan and pertechnetate thyroid scan or sestamibi scan
and I-123 thyroid scan. These procedures in this patient population are controversial but may be
appropriate.

n Variant

4: US parathyroid or CT neck without and
with IV contrast or sestamibi dual-phase scan neck or
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sestamibi dual-phase scan with SPECT or SPECT/CT
neck or sestamibi scan and I-123 thyroid scan with
SPECT or SPECT/CT neck or sestamibi scan and
pertechnetate thyroid scan or sestamibi scan and pertechnetate thyroid scan with SPECT or SPECT/CT
neck is usually appropriate as the initial imaging of all
patients with THPT. These procedures are equivalent
alternatives (ie, only 1 procedure will be ordered to
provide the clinical information to effectively manage
the patient’s care), although they may be used in a
complementary manner to maximize the accuracy and
conﬁdence of parathyroid localization via concordant
imaging results. The panel did not agree on recommending sestamibi scan and I-123 thyroid scan for this
clinical scenario. There is insufﬁcient medical literature
to conclude whether or not these patients would
beneﬁt from sestamibi scan and I-123 thyroid scan.
This procedure in this patient population is controversial but may be appropriate.

SUPPORTING DOCUMENTS
The evidence table, literature search, and appendix for
this topic are available at https://acsearch.acr.org/list. The
appendix includes the strength of evidence assessment
and the ﬁnal rating round tabulations for each
recommendation.
For additional information on the Appropriateness
Criteria methodology and other supporting documents go to
www.acr.org/ac.

RELATIVE RADIATION LEVEL INFORMATION
Potential adverse health effects associated with radiation
exposure are an important factor to consider when selecting
the appropriate imaging procedure. Because there is a wide
range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication
has been included for each imaging examination. The RRLs
are based on effective dose, which is a radiation dose
quantity that is used to estimate population total radiation
risk associated with an imaging procedure. Patients in the
pediatric age group are at inherently higher risk from
exposure, because of both organ sensitivity and longer life
expectancy (relevant to the long latency that appears to
accompany radiation exposure). For these reasons, the RRL
dose estimate ranges for pediatric examinations are lower as
compared with those speciﬁed for adults (see Table 2).
Additional information regarding radiation dose assessment
for imaging examinations can be found in the ACR
Appropriateness Criteria Radiation Dose Assessment
Introduction document [113].
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